Founded in 1989 and headquartered in Amman, Jordan, MS Pharma has grown into a prominent pharmaceutical group with a global reach. It employs over 2,000 people across at least 12 countries and maintains a corporate management office in Zug, Switzerland

The company manages multiple manufacturing facilities located across the Middle East and North Africa (MENA) region—specifically in Algeria, Jordan, and Saudi Arabia—and operates across a broad range of therapeutic areas, including oncology, cardiovascular, respiratory and central nervous system disorders

Key Products and Services

Generics and Specialty Medicines
Comprehensive portfolio spanning solids, liquids, cytotoxic drugs and sterile injectables across diverse therapeutic areas.

Biologics Manufacturing
The Middle East’s first biologics manufacturing facility in Riyadh, Saudi Arabia. GMP-approved and equipped for formulation, fill & finish, lyophilisation, and packaging of complex biologics such as monoclonal antibodies and peptides, meeting EMA and US FDA standards

Global Manufacturing Network
Four main production sites:

Algeria: Centre of excellence for solid dose, liquid and cream formulations (OTC & Rx).

Jordan (Sterile Site): Aseptic, terminal and lyophilised vials; large-volume parenterals; prefilled syringes.

Jordan (Non-Sterile Site): Solid dose, cephalosporins, liquids, creams, soft gelatin capsules, multi-layer tablets.

Saudi Arabia: Oral solids manufacturing with secondary packaging, plus the newly launched biologics facility

R&D and Analytical Development
In-house R&D team experienced in formulation development, process development, analytical methods, and scale-up across a variety of dosage forms

Marketing Authorisations and Molecules
Over 2,000 approved marketing authorisations, with around 300 INNs (International Non-Proprietary Names) and 170 international partnerships

With an expansive footprint across the MENA region and Switzerland, MS Pharma combines strong R&D capabilities, diversified manufacturing operations and an extensive product portfolio—including generics, specialty injectables, and biologics. Its latest achievement in establishing a GMP-approved biologics facility in Saudi Arabia reinforces its commitment to meeting global regulatory standards and supporting access to advanced therapies in the region and beyond.